Cargando…
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
PURPOSE: Receptor tyrosine kinase AXL (RTK-AXL) is regarded as suitable target in glioma therapy. Here we evaluate the anti-tumoral effect of small molecule inhibitor BMS-777607 targeting RTK-AXL in a preclinical glioma model and provide evidence that RTK-AXL is expressed and phosphorylated in prima...
Autores principales: | Onken, Julia, Torka, Robert, Korsing, Sören, Radke, Josefine, Krementeskaia, Irina, Nieminen, Melina, Bai, Xi, Ullrich, Axel, Heppner, Frank, Vajkoczy, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891090/ https://www.ncbi.nlm.nih.gov/pubmed/26848524 http://dx.doi.org/10.18632/oncotarget.7130 |
Ejemplares similares
-
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
por: Onken, Julia, et al.
Publicado: (2017) -
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
por: Scherschinski, Lea, et al.
Publicado: (2022) -
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
por: Dai, Yao, et al.
Publicado: (2012) -
Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019) -
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)